Research Interests

My lab is investigating c-Met signalling in cancer in the view of designing appropriate therapies. c-Met receptor, overexpressed or mutated in cancer, promotes cell proliferation, migration and survival. Thus c-Met is a major target and several c-Met inhibitors are in clinical trials.

We study c-Met endocytic trafficking and c-Met signalling in breast, lung and pancreatic cancer cells and patient tissues. We have demonstrated that “c-Met endosomal signaling” plays a role in cell transformation in vitro and in vivo. We are dissecting the mechanisms regulating c-Met endocytosis / trafficking. We are determining the “endosomal signals” and how they are regulated. We are assessing whether targeting c-Met endocytosis / trafficking or the endosomal signals reduce cell transformation in vitro and in vivo.

It is hoped that our research will help design appropriate therapies for c-Met driven cancer and overcome potential resistance to c-Met inhibitors.

Major Funders
• Breast Cancer Campaign
• Medical Research Council
• Cancer Research UK
• Barts and the London Charitable Foundation

Contact Details
Email: s.kermorgant@qmul.ac.uk
Recent Publications


